Fate Therapeutics Inc (FATE): Free Cash Flow
-$112.04M
Year ended 2025-12-31
-$105.66M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$112.04M | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | -$123.60M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$138.42M | n/m | 2025-03-05, From 2023-01-01 |
| 2022-12-31 | -$283.77M | n/m | 2024-02-26, From 2022-01-01 |
| 2021-12-31 | -$213.57M | n/m | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | -$44.16M | n/m | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | -$90.57M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$40.95M | n/m | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | -$38.54M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$30.28M | n/m | 2019-03-05, From 2016-01-01 |
| 2015-12-31 | -$19.89M | n/m | 2018-03-05, From 2015-01-01 |
| 2014-12-31 | -$23.30M | n/m | 2017-03-16, From 2014-01-01 |
| 2013-12-31 | -$15.62M | n/m | 2016-03-03, From 2013-01-01 |
| 2012-12-31 | -$13.98M | n/m | 2015-03-12, From 2012-01-01 |
| 2011-12-31 | -$12.15M | n/a | 2014-03-17, From 2011-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$112.04M | n/m |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$121.71M | n/m |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$741.0K | n/a |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$167.09M | n/m |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | -$93.83M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$57.15M | n/m |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | -$20.67M | n/m |
| TScan Therapeutics, Inc. (TCRX) | 2025-12-31 | -$139.73M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$132.48M | n/m |
Compare FATE, DBVT, ZEOX, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗